McKesson Corporation $MCK Shares Bought by Brandes Investment Partners LP

Brandes Investment Partners LP raised its holdings in McKesson Corporation (NYSE:MCK) by 2.1% during the 4th quarter, Holdings Channel reports. The firm owned 188,365 shares of the company’s stock after buying an additional 3,924 shares during the quarter. Brandes Investment Partners LP’s holdings in McKesson were worth $154,524,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Motley Fool Asset Management LLC grew its holdings in McKesson by 33.8% in the fourth quarter. Motley Fool Asset Management LLC now owns 11,491 shares of the company’s stock valued at $9,426,000 after purchasing an additional 2,904 shares during the period. Portfolio Design Labs LLC grew its holdings in McKesson by 3.5% in the fourth quarter. Portfolio Design Labs LLC now owns 3,257 shares of the company’s stock valued at $2,672,000 after purchasing an additional 110 shares during the period. Insight Advisors LLC PA grew its holdings in McKesson by 10.9% in the fourth quarter. Insight Advisors LLC PA now owns 294 shares of the company’s stock valued at $241,000 after purchasing an additional 29 shares during the period. Stonebrook Private Inc. purchased a new position in shares of McKesson in the fourth quarter valued at approximately $212,000. Finally, Pettyjohn Wood & White Inc. lifted its position in shares of McKesson by 22.2% in the fourth quarter. Pettyjohn Wood & White Inc. now owns 325 shares of the company’s stock valued at $267,000 after acquiring an additional 59 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $2,701,869.50. Following the transaction, the executive vice president owned 3,247 shares in the company, valued at approximately $2,471,259.23. This trade represents a 52.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of McKesson stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total value of $1,817,482.92. Following the transaction, the executive vice president owned 3,090 shares in the company, valued at approximately $2,351,768.10. The trade was a 43.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 6,893 shares of company stock worth $5,225,385. 0.08% of the stock is owned by corporate insiders.

McKesson Stock Performance

Shares of McKesson stock opened at $783.71 on Wednesday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The company has a market cap of $94.20 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 1.26 and a beta of 0.31. The business’s 50 day moving average price is $802.84 and its 200 day moving average price is $847.76.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The firm had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same quarter last year, the business posted $10.12 earnings per share. The firm’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, analysts predict that McKesson Corporation will post 44.28 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 8.53%.

Wall Street Analysts Forecast Growth

MCK has been the topic of several research reports. UBS Group raised their target price on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wells Fargo & Company decreased their target price on McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $875.00 target price on shares of McKesson in a research report on Friday, May 8th. Raymond James Financial set a $970.00 target price on McKesson in a research report on Thursday, March 5th. Finally, Bank of America decreased their target price on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $968.87.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.